We are Main Street
U.S.

Harrow Acquired TYRVAYA Nasal Spray Rights

The ophthalmology firm expanded its dry eye portfolio, adding $30 million in projected 2027 revenue and 40 staff members.

Updated on Oct. 6, 2026 in Healthcare

Bold flat-color editorial illustration of a sculptural glass ocular instrument in navy and cream, representing the precision of eye-care medical technology.
Harrow has acquired the worldwide commercial rights to the dry eye nasal spray TYRVAYA from Viatris, a move that adds 40 staff and bolsters the firm's ophthalmology portfolio. AI Illustration. Upload story photo >

Live Poll

Does consolidation of prescription brands by fewer companies generally improve access to affordable medications?

Harrow has completed the acquisition of worldwide commercial rights to the FDA-approved dry eye treatment TYRVAYA from Viatris, excluding Japan. The deal adds a second key dry eye asset to the company's lineup, following the integration of 40 commercial personnel from Viatris.

Why it matters

By adding TYRVAYA to its existing VEVYE treatment, Harrow is scaling its footprint in the U.S. dry eye market. The move allows the firm to consolidate its commercial infrastructure and product offerings for eye care practitioners.

Harrow paid $30 million in cash at closing with up to $70 million in contingent milestones, a deal the company expects to generate more than $30 million in revenue during 2027. The agreement also includes the transfer of 40 commercial employees from Viatris to the Harrow team.

The players

Harrow

A Nashville-based pharmaceutical company focused on ophthalmology products and prescription eye treatments.

Viatris

A global healthcare company with a broad portfolio of generic and branded medicines.

The details

Harrow secured worldwide rights to the nasal spray, which is approved for use in the U.S., China, and Taiwan, though Viatris retains rights in Japan and will pay royalties on net sales there. The deal involves the absorption of 40 former Viatris commercial staff into the Harrow organization, strengthening the company's existing dry eye sales force. TYRVAYA prescriptions will continue to be processed through retail pharmacies or PhilRx.

Timeline

  1. August 2026: Harrow announced the terms of the TYRVAYA acquisition.

  2. October 05, 2026: Harrow closed the acquisition of TYRVAYA.

  3. Q4 2026: Harrow will onboard 40 new commercial personnel.

  4. 2027: Harrow expects to generate $30 million in revenue from TYRVAYA.

Market Landscape

This acquisition mirrors the broader consolidation trend in specialty ophthalmology, where firms seek to capture market share by bundling therapeutic options for eye care. It marks a strategic expansion following the established FDA approval path for dry eye disease treatments.

Operators in the eye care space should monitor whether Harrow consolidates its sales force coverage or changes its prescribing support for both VEVYE and TYRVAYA. Practices should note that product distribution remains unchanged, with prescriptions still routed through retail channels or PhilRx.

The takeaway

This deal highlights the importance of scaling commercial teams to match an expanded product portfolio in niche markets. Practitioners should update their internal pharmacy referral lists to ensure smooth transitions for patients currently on TYRVAYA therapy.

What happens next

Harrow will complete the onboarding of the 40 new commercial personnel during the fourth quarter of 2026.

Further reading

For more on industry shifts in medical treatment delivery, visit the Healthcare section.

Live Poll

Does consolidation of prescription brands by fewer companies generally improve access to affordable medications?